Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities)

JACC. Heart Failure
|May 15, 2013
PubMed

Insights

Heart failure with preserved ejection fraction (HFpEF) is common in African Americans, more prevalent than reduced ejection fraction (HFrEF) heart failure. HFpEF has a better prognosis than HFrEF but worse than no heart failure.

Area of Science:

  • Cardiology
  • Public Health
  • Epidemiology

Background:

  • African Americans exhibit a higher risk of heart failure (HF).
  • Limited data exists on the specific characteristics and outcomes of HF with preserved ejection fraction (HFpEF) in this population compared to HF with reduced ejection fraction (HFrEF) and individuals without HF.

Purpose of the Study:

  • To compare clinical features, cardiac structure and function, and mortality among African Americans with HFpEF, HFrEF, and no HF.
  • To elucidate the unique aspects of HFpEF within an African American cohort.

Main Methods:

  • Analysis of the Jackson, Mississippi, ARIC study cohort (n=2,445) including middle-aged African Americans.
  • Echocardiography performed between 1993-1995 to assess left ventricular ejection fraction (LVEF).
  • Participants categorized into HFpEF (LVEF ≥50%), HFrEF (LVEF <50%), or no HF groups for comparative analysis.

Main Results:

  • Heart failure identified in 5.9% of participants; HFpEF constituted 73% of HF cases.
  • HFpEF patients were older, more frequently female, and had more comorbidities and concentric hypertrophy than those without HF.
  • Compared to HFrEF, HFpEF patients were less likely to have coronary heart disease, diabetes, chronic kidney disease, and eccentric hypertrophy; HFpEF was associated with a 1.51 HR for death vs. no HF, while HFrEF had a 2.50 HR vs. HFpEF.

Conclusions:

  • In middle-aged African Americans, HFpEF is the predominant form of heart failure.
  • HFpEF carries a significantly better prognosis than HFrEF.
  • The prognosis for HFpEF, while better than HFrEF, remains worse than in individuals without heart failure.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...